What does DR.COREMANS EN DR. NOWÉ do?

DR.COREMANS EN DR. NOWÉ is a specialist medical practice in Willebroek. Private Limited, started on 23 July 2004, 1 establishment.

What is the address of DR.COREMANS EN DR. NOWÉ?

The registered office of DR.COREMANS EN DR. NOWÉ is located at Dwarsstraat 9, 2830 Willebroek.

Is DR.COREMANS EN DR. NOWÉ still active?

Yes. According to the CBE (18 September 2026) DR.COREMANS EN DR. NOWÉ is active, legal situation “Normale toestand”, started on 23 July 2004.

Is DR.COREMANS EN DR. NOWÉ registered on Peppol?

Yes, DR.COREMANS EN DR. NOWÉ is registered on the Peppol network with ID 0208:0866656002.

What is the enterprise number of DR.COREMANS EN DR. NOWÉ?

The enterprise number of DR.COREMANS EN DR. NOWÉ is BE0866656002.

When was DR.COREMANS EN DR. NOWÉ founded?

DR.COREMANS EN DR. NOWÉ was founded on 23 July 2004.

Who are the directors of DR.COREMANS EN DR. NOWÉ?

According to the 2025 annual accounts, the directors of DR.COREMANS EN DR. NOWÉ are: Gisèle Nowé, Bart Coremans.

Is DR.COREMANS EN DR. NOWÉ a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 23 July 2004; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did DR.COREMANS EN DR. NOWÉ make in 2025?

DR.COREMANS EN DR. NOWÉ posted a profit after taxes of € 222,641 in financial year 2025.

What is the revenue of DR.COREMANS EN DR. NOWÉ?

As a small company, DR.COREMANS EN DR. NOWÉ is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 357,747.

DR.COREMANS EN DR. NOWÉ (Private Limited) - Willebroek

Dossier DR.COREMANS EN DR. NOWÉ, printed on 18 September 2026 from databakkes.be/en/0866656002/dr-coremans-en-dr-nowe. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

DR.COREMANS EN DR. NOWÉ from Willebroek, company number BE0866656002, closed financial year 2025 with a result of € 222,641 after tax. For that financial year DR.COREMANS EN DR. NOWÉ recorded a gross margin of € 357,747 and equity of € 1.6 million. Compared with financial year 2024, the result moved from € 216,853 to € 222,641. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.

What it is worth Growing

€ 1.6 million

▲ 10% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 222,641

▲ 3% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 254,354

▼ 42% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 32,323 paid out

15 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Wage cost

€ 29

▲ € 5,582 vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 116,086

▲ € 99,386 vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 64,950

▲ € 53,077 vs 2024

€ 24,595 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Taxes

€ 103,282

▲ 208% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 219,636 Gross margin 2022: € 219,636 First fiscal year in the series	€ 283,772 Gross margin 2023: € 283,772 ▲ 29% vs 2022 (€ 219,636) Favourable step	€ 308,212 Gross margin 2024: € 308,212 ▲ 9% vs 2023 (€ 283,772) Favourable step	€ 357,747 Gross margin 2025: € 357,747 ▲ 16% vs 2024 (€ 308,212) Favourable step	▲ 16%
Profit after taxes	€ 72,988 Profit after taxes 2022: € 72,988 First fiscal year in the series	€ 110,330 Profit after taxes 2023: € 110,330 ▲ 51% vs 2022 (€ 72,988) Favourable step	€ 216,853 Profit after taxes 2024: € 216,853 ▲ 97% vs 2023 (€ 110,330) Favourable step	€ 222,641 Profit after taxes 2025: € 222,641 ▲ 3% vs 2024 (€ 216,853) Favourable step	▲ 3%
Equity	€ 1,132,166 Equity 2022: € 1,132,166 First fiscal year in the series	€ 1,242,496 Equity 2023: € 1,242,496 ▲ 10% vs 2022 (€ 1,132,166) Favourable step	€ 1,459,349 Equity 2024: € 1,459,349 ▲ 17% vs 2023 (€ 1,242,496) Favourable step	€ 1,599,667 Equity 2025: € 1,599,667 ▲ 10% vs 2024 (€ 1,459,349) Favourable step	▲ 10%
Total debts	€ 78,758 Total debts 2022: € 78,758 First fiscal year in the series	€ 49,392 Total debts 2023: € 49,392 ▼ 37% vs 2022 (€ 78,758) Favourable step	€ 50,257 Total debts 2024: € 50,257 ▲ 2% vs 2023 (€ 49,392) Unfavourable step	€ 168,233 Total debts 2025: € 168,233 ▲ 235% vs 2024 (€ 50,257) Unfavourable step	▲ 235%
Cash	€ 117,199 Cash 2022: € 117,199 First fiscal year in the series	€ 26,338 Cash 2023: € 26,338 ▼ 78% vs 2022 (€ 117,199) Unfavourable step	€ 436,042 Cash 2024: € 436,042 ▲ € 409,704 vs 2023 (€ 26,338) Favourable step	€ 254,354 Cash 2025: € 254,354 ▼ 42% vs 2024 (€ 436,042) Unfavourable step	▼ 42%
Land & buildings	€ 306,228 Land & buildings 2022: € 306,228 First fiscal year in the series	€ 303,029 Land & buildings 2023: € 303,029 ▼ 1% vs 2022 (€ 306,228) Unchanged	€ 291,536 Land & buildings 2024: € 291,536 ▼ 4% vs 2023 (€ 303,029) Unchanged	€ 291,536 Land & buildings 2025: € 291,536 Unchanged (€ 291,536) Unchanged
Retained profit	€ 1,082,166 Retained profit 2022: € 1,082,166 First fiscal year in the series	€ 1,192,496 Retained profit 2023: € 1,192,496 ▲ 10% vs 2022 (€ 1,082,166) Favourable step	€ 1,409,349 Retained profit 2024: € 1,409,349 ▲ 18% vs 2023 (€ 1,192,496) Favourable step	€ 1,599,667 Retained profit 2025: € 1,599,667 ▲ 14% vs 2024 (€ 1,409,349) Favourable step	▲ 14%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 32,323 Dividend 2025: € 32,323 Unchanged (€ 0) Unchanged
Bank debt	€ 61,349 Bank debt 2022: € 61,349 First fiscal year in the series	€ 33,114 Bank debt 2023: € 33,114 ▼ 46% vs 2022 (€ 61,349) Favourable step	€ 11,873 Bank debt 2024: € 11,873 ▼ 64% vs 2023 (€ 33,114) Favourable step	€ 64,950 Bank debt 2025: € 64,950 ▲ € 53,077 vs 2024 (€ 11,873) Unfavourable step	▲ € 53,077
Balance sheet total	€ 1,210,924 Balance sheet total 2022: € 1,210,924 First fiscal year in the series	€ 1,291,888 Balance sheet total 2023: € 1,291,888 ▲ 7% vs 2022 (€ 1,210,924) Unchanged	€ 1,509,607 Balance sheet total 2024: € 1,509,607 ▲ 17% vs 2023 (€ 1,291,888) Unchanged	€ 1,767,900 Balance sheet total 2025: € 1,767,900 ▲ 17% vs 2024 (€ 1,509,607) Unchanged	▲ 17%

Key figures of DR.COREMANS EN DR. NOWÉ, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to DR.COREMANS EN DR. NOWÉ?

What happened at DR.COREMANS EN DR. NOWÉ in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 31, 2026 New annual accounts for financial year 2025: profit of € 222,641 (▲ 3% vs 2024). filed late Source: NBB ↗
2004 Gisèle Nowé became a director. NBB
2004 Bart Coremans became a director. NBB
Jul 23, 2004 New establishment in Mechelen. KBO
Jul 23, 2004 Start of the company according to the CBE. KBO

In short

From € 72,988 profit in 2022 to € 222,641 profit in 2025.

Paid € 288,328 in corporate taxes since 2022.

Best year ever: 2025, with € 222,641 profit.

Paid out € 32,323 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DR.COREMANS EN DR. NOWÉ? We notify you, reason included.

Follow DR.COREMANS EN DR. NOWÉ

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Gisèle Nowé Bart Coremans

DR.COREMANS EN DR. NOWÉ

Behind DR.COREMANS EN DR. NOWÉ are Gisèle Nowé and Bart Coremans.

See the full network in the app

Directors

According to the 2025 annual accounts

Gisèle Nowé

Manager

since 2004

Bart Coremans

Manager

since 2004

Establishments

Establishment units

Physical locations of this company

Registered office

Dwarsstraat 9

2830 Willebroek

2.229.590.530

Leopoldstraat 2

2800 Mechelen

Active since 23 July 2004

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0866.656.002
VAT number: BE 0866.656.002
Registered office: Dwarsstraat 9, 2830 Willebroek
Names & denominations: DR.COREMANS EN DR. NOWÉ
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 23 July 2004
Peppol: Active · Active since 22 Dec 2025
Activities · NACE: Activiteiten van medisch specialisten

View on CBE Public ↗ Annual accounts (NBB) ↗